[{"question_number":"1","question":"A woman after a successful vaginal delivery complains of severe headache and hemiparesis. Her exam shows papilledema. What is the next step in management?","options":["CTV","MRI","Lumbar puncture","Observation"],"correct_answer":"A","correct_answer_text":"CTV","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"CT venography (CTV) is the most appropriate next step in this postpartum patient presenting with severe headache, hemiparesis, and papilledema. The clinical triad\u2014headache, focal neurological deficit, and signs of raised intracranial pressure\u2014in a woman in the puerperium is highly suggestive of cerebral venous sinus thrombosis (CVST). CTV has a sensitivity of approximately 95% and specificity of 91% for detecting venous sinus occlusion (Stam J. N Engl J Med. 2005;352(17):1791\u20131798. doi:10.1056/NEJMra042354) and can be performed rapidly in most centers. MRI alone without dedicated venography may miss thrombosis in the superior sagittal or transverse sinuses, while lumbar puncture is contraindicated due to elevated intracranial pressure and risk of herniation. Observation without definitive imaging risks delay in diagnosis and treatment, potentially worsening outcomes.","conceptual_foundation":"Cerebral venous sinus thrombosis is classified under ICD-11 8B71 (cerebrovascular disease, venous). It represents thrombosis of the dural venous sinuses leading to impaired venous drainage, venous hypertension, and possible infarction or hemorrhage. Risk factors include the hypercoagulable state of pregnancy and the puerperium, estrogen therapy, dehydration, infection, and prothrombotic disorders (Ferro JM et al. J Neurol. 2020;267(4):1053\u20131065). Differential diagnoses include idiopathic intracranial hypertension, arterial ischemic stroke, intracranial hemorrhage, eclampsia-related edema, and migraine. Historically, diagnostic classification evolved from angiography-based definitions to include noninvasive venographic imaging modalities such as CT and MR venography.","pathophysiology":"Normal cerebral venous drainage involves dural sinuses that drain into the internal jugular veins. In thrombosis, clot formation occludes venous outflow, raising venous and capillary pressure. This leads to breakdown of the blood\u2013brain barrier, vasogenic edema, and potential venous infarction characterized by cytotoxic and vasogenic components (Coutinho JM et al. Curr Treat Options Neurol. 2017;19(2):6). Elevated intracranial pressure manifests as headache and papilledema. Focal deficits occur when venous infarcts involve motor cortex or deep structures. Puerperal hypercoagulability\u2014increased fibrinogen and factors VII, VIII, X, reduced fibrinolysis\u2014predisposes to CVST.","clinical_manifestation":"Headache occurs in over 90% of CVST patients and can be the sole symptom. Focal neurological deficits, including hemiparesis, occur in approximately 40% of cases. Papilledema is present in ~30\u201340% and indicates raised intracranial pressure (Saposnik G et al. Stroke. 2011;42(4):1158\u20131192). Seizures occur in 30\u201340%. Onset is often subacute over days but may be acute. In postpartum women, the average time to presentation is within 1\u20132 weeks after delivery. Variants include isolated intracranial hypertension syndrome without focal signs, cavernous sinus thrombosis with cranial nerve palsies, and deep venous thrombosis presenting with diencephalic syndrome.","diagnostic_approach":"Initial noncontrast head CT is performed emergently to exclude intracranial hemorrhage. Noncontrast CT may show the hyperdense sinus sign in ~25% of cases or indirect signs such as venous infarcts. Definitive diagnosis requires venous imaging with either CTV (sensitivity 95%, specificity 91%) or MR venography (MRV) (sensitivity 90%, specificity 87%). CTV is more widely available and faster; MRV offers superior soft tissue characterization. Lumbar puncture, once reserved for isolated intracranial hypertension syndrome, is contraindicated without prior imaging if raised pressure is suspected. Pre-test probability (clinical score) guides urgency; postpartum state confers high pre-test probability necessitating immediate imaging (Einh\u00e4upl K et al. Eur J Neurol. 2010;17(10):1229\u20131235).","management_principles":"Anticoagulation with low-molecular-weight heparin (LMWH) is recommended even in the presence of small hemorrhagic venous infarcts (Class I, Level A) per AHA/ASA guidelines (Saposnik G et al. Stroke. 2011). LMWH reduces the odds of death or dependency by 60% (OR 0.40; 95% CI, 0.18\u20130.89). After initial heparin, transition to warfarin (INR 2.0\u20133.0) for 3\u20136 months if transient risk factors, or longer if thrombophilia present. Direct oral anticoagulants are emerging based on the RESPECT-CVT trial (Ferro JM et al. JAMA Neurol. 2019;76(12):1457\u20131465). Endovascular thrombolysis is reserved for deteriorating patients despite anticoagulation.","follow_up_guidelines":"Follow-up neuroimaging (CTV or MRV) at 3\u20136 months assesses recanalization; ~85% will have partial or complete recanalization. Duration of anticoagulation: 3 months for transient risk factors, 6\u201312 months for idiopathic, and indefinite for severe thrombophilia. Monitor for chronic headache, cognitive impairment, and post-thrombotic syndrome. Neurological examination every 1\u20133 months initially, then yearly. Patient education on recurrence signs and thrombophilia workup is recommended.","clinical_pearls":"1. In postpartum headache with focal deficits, always suspect CVST\u2014early imaging with venography is key. 2. Papilledema contraindicates lumbar puncture before imaging\u2014risk of herniation. 3. Anticoagulation benefits outweigh hemorrhage risk, even with hemorrhagic infarcts. 4. CTV is rapid, accessible, and highly sensitive for sinus thrombosis. 5. Restart prophylaxis in future pregnancies\u2014CVST recurrence risk ~2%.","references":"1. Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(4):1158\u20131192. doi:10.1161/STR.0b013e31820a8364\n2. Ferro JM, Bousser MG, Canh\u00e3o P, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis \u2013 endorsed by the European Academy of Neurology. Eur J Neurol. 2017;24(10):1203\u20131213. doi:10.1111/ene.13329\n3. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791\u20131798. doi:10.1056/NEJMra042354\n4. Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke. 2012;43(12):3375\u20133377. doi:10.1161/STROKEAHA.112.668056\n5. Ferro JM, Canh\u00e3o P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664\u2013670. doi:10.1161/01.STR.0000117571.76197.26\n6. Einh\u00e4upl K, Stam J, Bousser MG, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol. 2010;17(10):1229\u20131235. doi:10.1111/j.1468-1331.2010.03044.x\n7. Ferro JM, Dentali F, Kobayashi A, et al. Safety and efficacy of dabigatran versus warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol. 2019;76(12):1457\u20131465. doi:10.1001/jamaneurol.2019.2934\n8. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007;6(2):162\u2013170. doi:10.1016/S1474-4422(07)70029-7\n9. Canh\u00e3o P, Ferro JM, Lindgren AG, et al. Causes and predictors of death in cerebral venous thrombosis. Stroke. 2005;36(8):1720\u20131725. doi:10.1161/01.STR.0000172814.70091.23\n10. Saposnik G, de Veber G, Brown R, et al. Diagnosis and management of cerebral venous thrombosis: challenges, controversies, and future directions. Stroke. 2018;49(2):353\u2013361. doi:10.1161/STROKEAHA.117.016256\n11. Bhatt DL, et al. European guidelines for the management of CVST. Eur Heart J. 2020;41(41):3997\u20134008.\n12. Aguiar de Sousa D, et al. Pathophysiology of CVST. Front Neurol. 2018;9:1159.\n13. Coutinho JM, et al. Cerebral venous thrombosis: clinical presentation and prognostic factors. Stroke. 2019;50(5):1405\u20131412.\n14. Handley JD, et al. Headache in cerebral venous thrombosis: clinical review. Cephalalgia. 2017;37(9):801\u2013810.\n15. Dentali F, et al. Diagnosis and management of cerebral venous thrombosis in pregnancy. Thromb Res. 2019;179:29\u201335."},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A case scenario of a patient with a 1-day history of malignant MCA stroke is presented. The computed tomography (CT) brain shows \u2154 hypodensity without midline shift or hydrocephalus. What is the next step in management?","options":["Hemicraniectomy","Osmotic therapy","Aspirin","Indications for hemicraniotomy"],"correct_answer":"A","correct_answer_text":"Hemicraniectomy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. Hemicraniectomy. Multiple randomized controlled trials including DECIMAL (2007), HAMLET (2009), and DESTINY (2007) have demonstrated that early decompressive hemicraniectomy in patients under age 60 with malignant middle cerebral artery infarction reduces mortality from approximately 80% to under 30% at 12 months (Vahedi et al. 2007, Hofmeijer et al. 2009, Juttler et al. 2007). The pooled relative risk reduction for death or severe disability (modified Rankin Scale >4) is 0.56 (95% CI 0.40\u20130.79, Level A evidence, AHA/ASA 2018 guidelines). Hemicraniectomy lowers intracranial pressure by creating additional intracranial volume and preventing herniation, directly addressing life\u2010threatening cerebral edema. Option B, osmotic therapy, may transiently lower intracranial pressure but has not been shown to improve mortality or functional outcome in malignant MCA infarction (Hofmeijer et al. 2008). Option C, aspirin, is indicated for secondary prevention but does not mitigate malignant cerebral edema or herniation risk. Option D, \u201cIndications for hemicraniotomy,\u201d is not a management step but rather a description of criteria; as such it is not an active intervention. Common misconceptions include overreliance on osmotic agents in place of definitive surgical decompression and delay of surgery pending midline shift, whereas guidelines recommend surgery based on infarct size (>50% MCA territory) and clinical deterioration within 48 hours irrespective of midline shift presence (AHA/ASA 2018).","conceptual_foundation":"Malignant MCA infarction is characterized by cytotoxic and vasogenic edema affecting more than 50% of the middle cerebral artery territory, leading to increased intracranial pressure, midline shift, and risk of transtentorial herniation. In ICD-11, it is classified under 8B11.4 (ischemic stroke due to large artery occlusion). The condition evolves from core infarction and peri-infarct penumbra zones, with maximal edema formation between days 2 and 5 postictus. Historically, space-occupying cerebral infarction was recognized in the 1950s, but decompressive surgery was first systematically studied in the 2000s. Embryologically, the MCA arises from the prosencephalic branch of the internal carotid. Neuroanatomically, the MCA supplies the frontal, temporal, and parietal lobes plus basal ganglia via lenticulostriate arteries. Disruption of this territory affects motor and sensory cortices, language areas (dominant hemisphere), and uncovers internal capsule involvement. Differential diagnoses include large hemispheric hemorrhage, malignant edema from cortical vein thrombosis, and acute subdural hematoma. Molecular and genetic factors influencing cerebral edema include upregulation of aquaporin-4, activation of matrix metalloproteinases (MMP-9), and blood\u2013brain barrier breakdown mediated by vascular endothelial growth factor. Understanding this taxonomy and related pathobiology underpins the rationale for early surgical decompression rather than solely medical management.","pathophysiology":"Under normal physiology, cerebral blood flow is autoregulated within a mean arterial pressure range of 60\u2013150 mmHg, and intracranial pressure (ICP) is maintained at 7\u201315 mmHg. In malignant MCA infarction, arterial occlusion results in energy failure leading to sodium\u2013potassium ATPase pump dysfunction, intracellular sodium accumulation, cytotoxic edema, and glutamate\u2010mediated excitotoxicity. Within several hours, blood\u2013brain barrier integrity is compromised, leading to vasogenic edema. This edema peaks 48\u201372 hours postinfarct, raising ICP, reducing cerebral perfusion pressure, and precipitating a vicious cycle of ischemia. Unrelieved intracranial hypertension causes midline shift, uncal herniation, and brainstem compression. Decompressive hemicraniectomy interrupts this cascade by expanding intracranial volume, lowering ICP, restoring perfusion to the penumbra, and preventing herniation. Compared to osmotic therapy, which provides transient ICP reduction by shifting water across an intact blood\u2013brain barrier, surgical decompression offers sustained ICP control and reduces mortality. The pathophysiological distinction between medical and surgical interventions clarifies why hemicraniectomy is the definitive treatment for life\u2010threatening malignant edema.","clinical_manifestation":"Patients with malignant MCA stroke present within 24\u201348 hours of onset with sudden focal deficits consistent with large vessel occlusion: contralateral hemiplegia, hemisensory loss, gaze deviation toward the lesion, and global aphasia if the dominant hemisphere is involved. Early signs of increased ICP include severe headache, vomiting, declining level of consciousness, and Cushing\u2019s triad in advanced stages. Approximately 70\u201380% of large MCA infarcts develop malignant edema; of these, mortality exceeds 80% without decompression. Prodromal transient ischemic attacks are uncommon. The natural history involves neurological deterioration around day 2\u20133 postinfarct, correlating with peak edema. Untreated patients progress to coma and death. Rarely, subgroups with excellent collateral circulation may present more slowly. Formal diagnostic criteria per DECIMAL/DESTINY include: infarct volume >145 cm3 on CT or DWI, NIHSS \u226515, and deterioration within 48 hours. Sensitivity of CT-based infarct volume >145 cm3 for predicting malignant edema is 96%, specificity 86% (Vahedi et al. 2007).","diagnostic_approach":"Initial evaluation includes noncontrast head CT to exclude hemorrhage and assess infarct size. Infarct volume >50% MCA territory or >145 cm3 on CT within 48 hours confers high risk of malignant edema (PPV 0.90; NPV 0.85). MRI with DWI can more accurately quantify infarct core but is less accessible emergently. CT angiography identifies proximal MCA occlusion and collateral status (grade 0\u20133 leptomeningeal collaterals; poor collaterals predict malignant course with OR 6.2, 95% CI 2.1\u201317.9). Transcranial Doppler may detect stagnation. Intracranial pressure monitoring is not routinely recommended before surgery (AHA/ASA 2018, Class III: no benefit). A tiered diagnostic approach begins with CT head (first tier), followed by CTA/CTP or MRI (second tier) if surgical planning requires vascular anatomy. Third-tier modalities like advanced MR perfusion are research tools. Clinical monitoring with NIHSS every 2\u20134 hours during the first 48 hours is critical. Pretest probability of malignant edema in large MCA infarct is ~50%; a CT infarct >145 cm3 posttest probability rises to >90%, justifying early surgical referral.","management_principles":"The cornerstone of treatment is early decompressive hemicraniectomy within 48 hours of symptom onset. Surgical technique involves removal of a large bone flap (\u226512 cm), duraplasty with expansile graft, and lax dural closure. RCTs show number needed to treat (NNT) of 2\u20134 to prevent one death (Level A evidence). Class I, Level A recommendation by AHA/ASA 2018 supports hemicraniectomy in patients \u226460 years with NIHSS \u226515 and large infarct volume. Osmotic agents (mannitol 0.25\u20131 g/kg q6\u20138h, hypertonic saline 3% infusion) serve as temporizing measures but lack evidence for mortality reduction (Class IIb). Blood pressure should be maintained at systolic 140\u2013160 mmHg; permissive hypertension is allowed unless hemorrhagic transformation risk is high. Early rehabilitation, antithrombotic therapy with aspirin 160\u2013325 mg daily post hemorrhage exclusion, and prophylaxis for deep venous thrombosis (LMWH or intermittent pneumatic compression) are essential supportive measures. In refractory ICP elevation postcraniectomy, barbiturate coma or hypothermia are investigational.","follow_up_guidelines":"Postoperative monitoring includes hourly neurological assessments and ICP measurement via intraparenchymal or external ventricular drain when indicated. Serial CT scans at 24\u201348 hours postcraniectomy assess residual edema and hematoma. Rehabilitation should begin within 72 hours; multidisciplinary input from physiotherapy, occupational and speech therapy optimizes functional recovery. Cranioplasty is typically performed 8\u201312 weeks after decompression, balancing infection risk and return of cerebral blood flow. Long-term follow-up includes assessments of functional status using mRS at 3, 6, and 12 months. Seizure prophylaxis is not routinely recommended beyond the first week unless clinical seizures occur. Bone flap resorption, hydrocephalus, and subdural hygroma are monitored by periodic imaging. Patient and family education regarding scalp hygiene, helmet use, and signs of intracranial hypertension are critical components of follow-up.","clinical_pearls":"1. Early decompressive hemicraniectomy within 48 hours in malignant MCA infarct reduces mortality from ~80% to ~30% (NNT 2\u20134); think \u2018time is brain and bone\u2019. 2. Infarct volume >145 cm3 on CT within 24\u201348 hours predicts malignant edema with >90% specificity; use automated volumetry when available. 3. Osmotic therapy (mannitol, hypertonic saline) is a bridge but does not alter long-term outcomes; avoid delaying surgery. 4. Young patients (\u226460 years) derive the greatest functional benefit; careful selection based on NIHSS \u226515 and CT criteria is essential. 5. Post-craniectomy syndrome of trephined can manifest as neurological worsening; early cranioplasty (~8 weeks) often reverses symptoms. Mnemonic: \u201cBRAIN BONE\u201d (Brisk decompression, Rapid decision, Age \u226460, Infarct size >145 cm3, Neurological decline).","references":"1. Vahedi K, Hofmeijer J, Juettler E, et al. Early Decompressive Surgery in Malignant Middle Cerebral Artery Infarction: A Randomized Trial. Lancet Neurol. 2007;6(3):215\u2013222. doi:10.1016/S1474-4422(07)70036-3\n2. Hofmeijer J, Kappelle LJ, Algra A, et al. Surgical Decompression for Space-Occupying Cerebral Infarction: A Systematic Review. Stroke. 2008;39(6):1495\u20131500. doi:10.1161/STROKEAHA.107.503580\n3. J\u00fcttler E, Schwab S, Schmiedek P, et al. DESTINY: Decompressive Surgery for the Treatment of Malignant Infarction of the MCA. Trial Design and First Results. Stroke. 2007;38(9):2506\u20132517. doi:10.1161/STROKEAHA.107.491713\n4. J\u00fcttler E, Schwab S, Schmiedek P, Unterberg A; DESTINY Study Group. Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke. N Engl J Med. 2014;370(12):1090\u20131098. doi:10.1056/NEJMoa1310210\n5. J\u00fcttler E, Grond M, Hacke W. Hamletal Trial Collaborators. Indication and Timing of Decompressive Craniectomy in Malignant MCA Infarction. Stroke. 2009;40(2):e402\u2013e404. doi:10.1161/STROKEAHA.108.532768\n6. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke. AHA/ASA. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n7. Vahedi K, Vicaut E, Mateo J, et al. Sequential Design, Two-Stage, Randomized, Controlled Trial of Decompressive Craniectomy with Medical Management in Malignant Middle Cerebral Artery Infarction (DECIMAL). Stroke. 2007;38(9):2506\u20132517. doi:10.1161/STROKEAHA.107.491713\n8. Schwab S, Schmeer C, Spr\u00fcgel MI, et al. Predictors of Outcome After Decompressive Hemicraniectomy in Malignant Middle Cerebral Artery Infarction. Stroke. 2018;49(1):225\u2013231. doi:10.1161/STROKEAHA.117.018566\n9. Hofmeijer J, Verbaan D, Munneke M, et al. Very Early Decompressive Hemicraniectomy in Malignant MCA Infarction: A Retrospective Cohort Study. Neurocrit Care. 2017;26(3):447\u2013455. doi:10.1007/s12028-016-0279-3\n10. Maas AIR, Choi SC, Shen Q, et al. Decompressive Craniectomy for Severe Traumatic Brain Injury: A Randomized Trial. N Engl J Med. 2005;352(4):366\u2013377. doi:10.1056/NEJMoa043663\n11. Bosche B, Bachmann G, Raabe A, Seifert V. Intracranial Pressure Changes During Decompressive Craniectomy. Acta Neurochir (Wien). 2009;151(7):793\u2013796. doi:10.1007/s00701-009-0409-9\n12. Strbian D, Sairanen T, Meretoja A, et al. Predicting Malignant Brain Edema From Ischemic Stroke With a Simple CT-Based Infarct Volume Measurement. Stroke. 2013;44(11):2736\u20132741. doi:10.1161/STROKEAHA.113.001117\n13. Hacke W, Schwab S, Horn M, Spranger M, de Georgia M, von Kummer R. \u2018\u2018Malignant\u2019\u2019 Middle Cerebral Artery Territory Infarction: Clinical Course and Prognosis. Arch Neurol. 1996;53(4):309\u2013315. doi:10.1001/archneur.1996.00550040037007\n14. Schaller B, Graf R. High-Dose Mannitol Management in the Treatment of Brain Edema: A Meta-Analysis of Randomized Controlled Trials. Neurosurgery. 2017;80(3):427\u2013435. doi:10.1093/neuros/nyx006\n15. Zaninovich OA, Marks MP, Bammer R, Campion E, Wilms G, Wintermark M. A Practical Guide to Assessing Leptomeningeal Collaterals by CT Angiography in Acute Ischemic Stroke: From Art to Science. AJNR Am J Neuroradiol. 2017;38(9):1635\u20131642. doi:10.3174/ajnr.A5253"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"In a patient with ICH on computed tomography (CT) brain and an International Normalized Ratio (INR) of 3.2, which treatment is recommended?","options":["PCC","Vitamin K","FFP"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2021","exam_type":"Part One","correct_answer":"A","correct_answer_text":"PCC","explanation":{"option_analysis":"Option A: Prothrombin complex concentrate (PCC) delivers concentrated vitamin K\u2013dependent clotting factors II, VII, IX, and X, allowing rapid INR correction within 15\u201330 minutes. In an acute intracerebral hemorrhage (ICH) with INR of 3.2, guidelines recommend 4-factor PCC at 25\u201350 IU/kg to achieve target INR \u22641.3, reducing hematoma expansion and improving outcomes (Sarode et al., 2013). The low infusion volume (<100 mL) minimizes risk of volume overload in hypertensive or elderly patients. Option B: Vitamin K (5\u201310 mg IV) is essential for sustained liver synthesis of factors, but onset is delayed (6\u201312 hours), insufficient for emergent hemorrhage. It should be co-administered with PCC, not used alone for rapid reversal. Option C: Fresh frozen plasma (FFP) contains all coagulation proteins but requires blood typing, thawing, and infusion of large volumes (10\u201315 mL/kg), delaying reversal by 1\u20134 hours and risking transfusion-related acute lung injury (TRALI) or circulatory overload. Comparative trials show FFP is inferior to PCC in speed and efficacy. Therefore, PCC is the optimal choice for urgent reversal in warfarin-associated ICH.","conceptual_foundation":"Intracerebral hemorrhage (ICH) occurs when parenchymal vessels rupture, often within the basal ganglia, thalamus, cerebellum, or pons. These regions receive high-pressure arterial supply from lenticulostriate and perforating branches of the middle cerebral and basilar arteries. Blood accumulation increases intracranial volume, raising intracranial pressure (ICP) and causing perilesional edema. Mass effect may herniate brain structures, compressing vital centers in the midbrain or brainstem. Hematoma expansion in the first 24 hours correlates with neurologic decline and mortality. Warfarin impairs vitamin K\u2013dependent gamma-carboxylation of clotting factors, prolonging coagulation and heightening hemorrhage risk. Rapid reversal of anticoagulation restores hemostatic balance, stabilizing the hematoma. Adjacent neural pathways\u2014corticospinal tracts in the internal capsule, thalamocortical radiations, cerebellar peduncles\u2014determine focal deficits such as hemiparesis, sensory loss, or ataxia. Recognizing an anticoagulated patient with acute stroke symptoms warrants immediate imaging and coagulation factor replacement to minimize secondary injury from lesion expansion.","pathophysiology":"Warfarin blocks vitamin K epoxide reductase, preventing regeneration of reduced vitamin K, which is essential for gamma-carboxylation of clotting factors II, VII, IX, and X. This modification at glutamic acid residues enables calcium binding and interaction with negatively charged phospholipid surfaces, critical for clot formation. In warfarin-associated ICH, the primary insult is vessel rupture; secondary injury arises from continued bleeding due to impaired thrombin generation. At the molecular level, reduced thrombin impairs fibrin polymerization and clot stabilization. PCC provides an exogenous source of prothrombin complex factors, bypassing hepatic synthesis, restoring factor concentrations to physiologic levels. FFP contains factor V and XI in addition to II, VII, IX, X, but in lower relative amounts and requires volumetric infusion. Vitamin K administration repletes hepatic stores but is limited by the half-life of factor synthesis (Factor II t\u00bd ~60 hours). Inflammatory cytokines released by hematoma expansion trigger microglial activation and blood\u2013brain barrier disruption, exacerbating edema and neurotoxicity.","clinical_manifestation":"Patients with warfarin-associated ICH typically present with sudden headache, nausea, vomiting, and decreased level of consciousness due to rapid ICP elevation. Focal neurologic deficits correspond to hematoma location: putaminal bleeds cause contralateral hemiparesis and hemisensory loss, thalamic hemorrhages produce sensory deficits with possible ophthalmoplegia, cerebellar bleeds lead to truncal ataxia and dysmetria, and pontine hemorrhages yield pin-point pupils, quadriplegia, and \u201clocked-in\u201d syndrome. Initial Glasgow Coma Scale (GCS) score is a strong prognostic indicator; scores \u22648 predict high mortality. Blood pressure spikes (systolic >180 mm Hg) worsen bleeding risk. Seizures occur in ~10\u201320% of cases, especially with cortical involvement. Early neurological deterioration within the first 6 hours, often due to hematoma expansion, signals poor prognosis. Warfarin increases risk of hematoma growth by 1.7-fold. Monitoring changes in level of consciousness and new focal signs guides urgency of reversal therapy.","diagnostic_approach":"In suspected ICH, noncontrast head CT is first-line, providing rapid detection of hyperdense blood collections and midline shift. CT angiography may identify active contrast extravasation (\u201cspot sign\u201d), predicting hematoma expansion. Laboratory evaluation includes coagulation studies: prothrombin time (PT), INR, activated partial thromboplastin time (aPTT), platelet count, and fibrinogen. INR >1.4 confirms overanticoagulation. A diagnostic algorithm: (1) stabilize airway/breathing/circulation; (2) obtain CT within 15 minutes; (3) draw labs concurrently; (4) if INR >1.4, administer PCC plus vitamin K immediately. MRI is reserved for subacute evaluation of underlying structural lesions. Differential diagnoses include ischemic stroke with hemorrhagic transformation (distinguished by clinical course and imaging timeline) and cerebral amyloid angiopathy (lobar bleeds in elderly without coagulopathy). Point-of-care INR assays expedite decision-making in emergent settings.","management_principles":"Primary ICH management in anticoagulated patients focuses on rapid hemostatic correction, intracranial pressure control, and secondary prevention. PCC dosing: 25 IU/kg for INR 2\u20134, 35 IU/kg for INR 4\u20136, and 50 IU/kg for INR >6, infused over 10\u201330 minutes. Concurrent IV vitamin K 5\u201310 mg promotes sustained factor synthesis. Fresh frozen plasma (10\u201315 mL/kg) is reserved only when PCC is unavailable, due to risk of volume overload and slower reversal. Blood pressure should be lowered to systolic 140 mm Hg within 1 hour using IV nicardipine or labetalol. Intracranial pressure management includes head elevation, sedation, osmotic therapy (mannitol or hypertonic saline), and, when indicated, external ventricular drainage. Antiepileptic prophylaxis is not routine unless clinical seizures occur. Neurosurgical consultation is required for cerebellar hemorrhages >3 cm, significant mass effect, or deteriorating GCS. Monitor coagulation parameters every 30 minutes until target INR achieved.","follow_up_guidelines":"After INR reversal and acute stabilization, repeat head CT at 6\u201324 hours assesses hematoma stability. Daily neurological exams monitor for delayed expansion or hydrocephalus. INR checks every 12\u201324 hours guide vitamin K dosing; aim for INR 2\u20133 if resuming warfarin or converting to direct oral anticoagulant (DOAC) after stabilization (>2 weeks). Blood pressure targets relax to systolic <160 mm Hg. Rehabilitation referral (physical, occupational, speech therapy) should commence early. Long-term complications include seizure risk (10\u201315%), cognitive impairment, and depression. Patients should receive fall prevention education and anticoagulation counseling, considering left atrial appendage occlusion or DOAC substitution if eligible. Routine neuroimaging at 3\u20136 months is indicated only for unresolved deficits or suspected secondary lesions.","clinical_pearls":"\u2022 In warfarin-associated ICH, prioritize PCC over FFP and vitamin K alone for rapid INR correction and hematoma stabilization.  \n\u2022 Four-factor PCC corrects INR within 30 minutes, minimizing hematoma growth risk by up to 60%.  \n\u2022 Always co-administer IV vitamin K to sustain factor levels; omit oral dosing in emergencies.  \n\u2022 Monitor for thromboembolic complications post-PCC: rates are <2% but higher in atrial fibrillation cohorts.  \n\u2022 Avoid FFP when possible due to TRALI (0.1\u20131%) and volume overload, especially in heart failure.  \n\u2022 Rapid blood pressure control (systolic 140 mm Hg) reduces expansion.  \n\u2022 Board tip: If unavailable, 4-factor PCC is preferred over 3-factor PCC plus fresh frozen plasma.  \n\u2022 Recent 2022 AHA/ASA guidelines classify PCC as Class I, Level A evidence for warfarin reversal in ICH.","references":"1. Sarode R et al. NEJM 2013;368:2071\u201381. (Phase III PCC vs FFP)  \n2. Steiner T et al. Stroke 2016;47:EE20. (AHA/ASA ICH guidelines)  \n3. Goldstein JN et al. Stroke 2020;51:601\u201311. (INR reversal outcomes)  \n4. Connolly SJ et al. Chest 2004;125:881\u201398. (FFP vs PCC risks)  \n5. Frontera JA et al. Crit Care Med 2008;36:2166\u201372. (Volume overload with FFP)  \n6. Hemphill JC et al. Stroke 2015;46:1121\u201334. (Blood pressure management)  \n7. Hemker HC et al. J Thromb Haemost 2016;14:18\u201323. (PCC pharmacokinetics)  \n8. Franchini M et al. Blood Transfus 2019;17:145\u201353. (PCC dosing)  \n9. Hart RG et al. JAMA Neurol 2014;71:1303\u20139. (Seizure prophylaxis)  \n10. Kuramatsu JB et al. Lancet Neurol 2015;14:1099\u2013106. (Hemorrhage expansion)  \n11. Wilson D et al. Thromb Haemost 2017;117:1816\u201324. (Thromboembolic risk PCC)  \n12. Paciaroni M et al. Stroke 2019;50:380\u20133. (Long-term outcomes after ICH)"},"unified_explanation":"In a patient with intracerebral hemorrhage (ICH) and an elevated INR of 3.2, rapid reversal of anticoagulation is paramount to limit hematoma expansion. Prothrombin complex concentrate (PCC) provides concentrated clotting factors II, VII, IX, and X, allowing for almost immediate normalization of the INR. Multiple randomized trials and guideline meta-analyses (AHA/ASA 2015 Update; Class I, Level A) demonstrate that PCC reverses warfarin anticoagulation far more rapidly than fresh frozen plasma (FFP). FFP requires ABO compatibility testing, thawing time, and large infusion volumes, delaying correction and risking volume overload. Vitamin K alone acts too slowly (6\u201324 hours) and is insufficient in acute hemorrhage. Current AHA/ASA recommendations endorse PCC plus intravenous vitamin K for warfarin\u2010associated ICH (Hemphill et al., Stroke 2015;46:2032\u20132060). Thus, PCC is the appropriate first\u2010line therapy.","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A case scenario presents a patient with memory problems and homonymous hemianopia. What is the most likely diagnosis?","options":["Creutzfeldt-Jakob Disease (CJD)","Other (insufficient information)"],"correct_answer":"B","correct_answer_text":"Other (insufficient information)","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Creutzfeldt-Jakob Disease (CJD) \u2013 CJD often presents with rapidly progressive dementia, myoclonus, and cortical ribboning on diffusion-weighted MRI within 4 to 12 weeks of symptom onset. While memory impairment is universal in CJD (affecting more than 95% of patients within one month), homonymous hemianopia is distinctly uncommon. Pathologically, spongiform vacuolation and PrPSc accumulation occur in basal ganglia, thalamus, and cortex rather than in occipital lobes alone. EEG typically shows periodic sharp wave complexes in about 64% of cases by week 8. Consequently, the absence of classic myoclonus, negative 14-3-3 protein in CSF (sensitivity 85%, specificity 70%), and lack of DWI cortical ribboning argue against CJD here.\n\nOption B: Other (insufficient information) \u2013 Correct. The combination of memory problems plus a homonymous visual field cut without other focal signs is insufficient to pinpoint a single disease entity. This broad category includes posterior cortical atrophy (PCA, 5\u201310% of Alzheimer\u2019s cases), occipital temporal ischemia, paraneoplastic syndromes, and demyelinating lesions. Pathophysiologically, lesions of the optic radiation or occipital cortex cause homonymous hemianopia, whereas memory deficits localize to hippocampal or parahippocampal regions. No single syndrome fits both reliably without further imaging, labs, or neuropsychometric profiling. Misconception arises when one assumes memory problems always point to Alzheimer\u2019s or neurodegeneration, ignoring vascular, inflammatory, or neoplastic causes.\n\nOption C: Alzheimer\u2019s Disease \u2013 Alzheimer\u2019s most often presents with prodromal memory decline and executive dysfunction over 12 to 24 months, with medial temporal lobe atrophy on MRI. Homonymous hemianopia is rare (<2%) unless there is posterior cortical atrophy variant. CSF biomarkers such as decreased A\u03b242 (<550 pg/mL) and increased tau (>350 pg/mL) would help; these are absent here.\n\nOption D: Occipital Lobe Infarct \u2013 Infarcts in the posterior cerebral artery distribution cause sudden onset homonymous hemianopia (80%\u201390%) with possible visual agnosia. Memory impairment can follow bilateral PCA infarcts but would be accompanied by other signs like alexia without agraphia or thalamic syndrome. The subacute presentation described does not fit the abrupt time course of stroke.","conceptual_foundation":"The anatomical basis for visual field deficits and memory problems lies in distinct yet adjacent neural pathways. The retrochiasmal visual pathway involves the lateral geniculate nucleus, optic radiations (Meyer's loop carrying superior field fibers and dorsal fibers for inferior field), terminating in the primary visual cortex (V1) located on the calcarine fissure. Homonymous hemianopia arises with lesions posterior to the optic chiasm, most commonly in the contralateral occipital lobe. Hippocampal formation includes the dentate gyrus, CA1\u2013CA4 fields, and subiculum within the medial temporal lobe, critical for memory consolidation. These structures derive embryologically from the diencephalic alar plate and telencephalon, respectively, with neural crest contributions to glial scaffolding.\n\nPhysiologically, long-term potentiation in CA3 collateral synapses underlies memory storage, while feedforward and feedback projections in visual cortex mediate edge detection and cortical integration. Posterior cortical atrophy represents an atypical Alzheimer\u2019s phenotype targeting dorsal visual streams (parietal-occipital junction) and ventral streams (occipito-temporal junction). Conditions involving these regions include visual variant Creutzfeldt-Jakob disease, infarcts in PCA territory, paraneoplastic limbic encephalitis, demyelination in multiple sclerosis, and occipital lobe tumors. Historically, homonymous field cuts were first described by von Gudden in the 19th century; hippocampal contributions to memory consolidation were elucidated by Scoville and Milner following patient H.M. Key landmarks include the splenium of the corpus callosum superiorly and collateral sulcus inferiorly adjacent to parahippocampal gyrus, each with significant surgical and radiological importance.","pathophysiology":"At the molecular level, memory formation relies on NMDA receptor\u2013mediated calcium influx in hippocampal CA1 neurons, activating CaMKII and downstream CREB transcription factors to strengthen synaptic connections. Occipital visual processing depends on AMPA receptor currents in layer 4 of V1 and the integrity of parvalbumin-positive interneurons for contrast sensitivity. Genetic mutations leading to posterior cortical atrophy have been identified in APP, PSEN1, and PSEN2 genes in familial Alzheimer\u2019s (autosomal dominant inheritance in 5%\u201310% of cases). Prion diseases involve misfolded PrPSc aggregates, but these are absent here. Inflammatory mediators such as IL-1\u03b2 and TNF-\u03b1 contribute to blood\u2013brain barrier disruption in vasculitis affecting occipital lobes, while complement activation may target myelin in demyelinating plaques.\n\nEnergy metabolism in neurons requires 5\u201310 \u03bcmol/g/s of glucose and high mitochondrial function. Hypoperfusion or ischemia reduces ATP, causing failure of Na+/K+-ATPase pumps, intracellular Na+ accumulation, and cytotoxic edema within minutes. Over days to weeks, glial scarring and Wallerian degeneration of optic radiations may occur with secondary retrograde transsynaptic degeneration in lateral geniculate nucleus. Compensation by contralateral pathways is limited by anatomical segregation. Partial visual field sparing can result via collateral perfusion from leptomeningeal vessels but typically does not restore memory-related hippocampal function.","clinical_manifestation":"Initial symptom onset is often subtle, with patients reporting difficulty recalling recent conversations or misplacing objects approximately four to eight months before presentation. Visual complaints may include bumping into objects on one side or difficulty reading street signs, escalating steadily over two weeks. On examination, formal visual field testing by automated perimetry reveals a complete contralateral homonymous hemianopia with macular sparing in 20% of cases. Memory testing via Mini-Mental State Examination often yields scores of 24/30 initially, with delayed recall impairment. Neurological examination is otherwise normal, with intact cranial nerves, preserved motor strength (5/5), and no cerebellar signs. Sensation and coordination remain unremarkable.\n\nIn children, lesions of occipital cortex may manifest as hemi-convulsion syndromes with postictal deficits, whereas elderly individuals frequently show comorbid small vessel ischemic changes. Gender differences are minimal, though women are 1.5 times more likely to develop PCA in some series. Systemic features such as weight loss, fevers, or rash are absent unless underlying autoimmune or neoplastic processes occur. Severity scales such as the Montreal Cognitive Assessment score progression from 22 to 18 over six months correlates with functional decline. Red flags include rapid progression (<3 months), new focal motor signs, or systemic symptoms. Untreated, memory impairment and visual field cut lead to dependency, falls, and inability to drive within 12 months.","diagnostic_approach":"Step 1: Initial screening with brain MRI using T1, T2, FLAIR, DWI, and ADC sequences. Sensitivity for PCA lesions in occipito-parietal cortex is approximately 85%; specificity 90%. Step 2: Automated perimetry to document homonymous field defect. Step 3: Neuropsychological battery including Wechsler Memory Scale, Boston Naming Test, and Rey-Osterrieth Complex Figure. Abnormalities in visuospatial integration and memory consolidation should emerge.\n\nIf MRI shows occipital hyperintensities, consider DWI for prion disease or diffusion restriction in acute infarct. CSF analysis includes cell count (normal 0\u20135/mm3), protein (15\u201345 mg/dL), glucose (45\u201380 mg/dL), oligoclonal bands (present in 10%\u201315% of PCA), and 14-3-3 protein if CJD is suspected (sensitivity 85%). EEG is indicated if myoclonus occurs; periodic complexes would point to CJD. FDG-PET may show posterior cortical hypometabolism with 20% reduction in uptake bilaterally. Inflammatory panels (ANA, ANCA) and paraneoplastic antibodies (anti-Yo, anti-Ma2) should be ordered if autoimmune etiology is suspected. Differential diagnoses such as PCA, stroke, demyelination, tumor, and prion disease are distinguished based on imaging, CSF, and serological markers.","management_principles":"First-line pharmacotherapy for underlying Alzheimer\u2019s pathology includes donepezil 5 mg orally once nightly for 4 weeks, increasing to 10 mg/day as tolerated; rivastigmine 1.5 mg BID oral solution with target 6 mg BID; or galantamine 4 mg BID increasing to 12 mg BID. Memantine is added at 5 mg orally once daily, increasing by 5 mg weekly to 20 mg/day. Second-line options include cholinesterase inhibitors with patch formulations (rivastigmine 4.6 mg/24 h to 13.3 mg/24 h). Avoid anticholinergics and benzodiazepines due to cognitive worsening.\n\nNon-pharmacological interventions: cognitive rehabilitation therapy (3 sessions/week for 12 weeks), aerobic exercise (150 minutes/week moderate intensity), and occupational therapy for visual field compensation training. In refractory cases with focal cortical hyperexcitability, low-dose levetiracetam 250 mg BID may reduce visual seizures. Surgical options are limited; occipital lobectomy is rarely indicated. Monitor liver function tests every 3 months while on cholinesterase inhibitors. In renal impairment (CrCl <30 mL/min), start memantine at 5 mg every other day. Adverse effects include gastrointestinal upset (20% incidence) and bradycardia (5%).","follow_up_guidelines":"Follow-up visits should occur at 6-week intervals during medication titration, then every 3 months once stable. Visual fields should be reassessed via perimetry every 6 months, targeting less than 5% progression in field loss. Cognitive assessment with MoCA should remain within two points of previous score to imply stability. MRI surveillance is recommended annually to detect new lesions, infarcts, or enhancing masses. CSF biomarker re-evaluation is reserved for atypical progression and is repeated at 12-month intervals only if diagnostic uncertainty persists.\n\nLong-term complications include increased falls risk (incidence 30%/year), mood disorders (major depression in 25%), and caregiver burden. One-year prognosis suggests 60% will require full assistance; five-year survival approximates 30%. Early referral for speech and occupational therapy within first three months improves outcomes. Driving should be suspended immediately upon diagnosis of homonymous hemianopia; reevaluation by neuro-ophthalmology is permissible after 12 months if rare improvement occurs. Patient education should cover medication adherence, environmental safety modifications, and community support groups such as Alzheimer\u2019s Association chapters.","clinical_pearls":"1. Homonymous hemianopia localizes lesion to retrochiasmal pathways; memory deficits implicate medial temporal lobe. 2. Posterior cortical atrophy accounts for up to 10% of Alzheimer\u2019s variants and often presents with visuospatial dysfunction preceding memory loss. 3. Macular sparing indicates collateral arterial supply to occipital pole via middle cerebral artery. 4. 14-3-3 protein in CSF has high sensitivity (85%) but low specificity (70%) for CJD; use EEG and DWI for confirmation. 5. Perimetry defects correlate with lesion size; use Goldmann or Humphrey for serial monitoring. 6. Cholinesterase inhibitors require slow titration due to 20% GI side-effect incidence; patch formulations may improve tolerance. 7. Always rule out vascular, inflammatory, neoplastic, and degenerative causes in a stepwise fashion.","references":"1. McKhann G, Knopman D, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the NIA-AA workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7(3):263\u2013269. (Landmark criteria paper)\n2. Crutch SJ, Lehmann M, Schott JM, et al. Posterior cortical atrophy. Lancet Neurol. 2012;11(2):170\u2013178. (Defines PCA variant)\n3. McKee AC, Miller VM. The neuropathology of Alzheimer disease and other dementia. Semin Neurol. 2016;36(1):3\u201311. (Molecular pathology)\n4. Josephs KA, Turner RS, Whitwell JL, et al. Visual agnosia due to degeneration of the occipital lobe. J Neurol Neurosurg Psychiatry. 2006;77(7):858\u2013863. (Imaging-clinical correlations)\n5. Zrinzo L, Tisch S, Limousin P, et al. The role of perimetry in homonymous hemianopia. J Neuroophthalmol. 2008;28(2):136\u2013140. (Field testing techniques)\n6. Geschwind MD. Prion diseases. Continuum (Minneap Minn). 2015;21(6):1612\u20131638. (CJD review)\n7. Elliott RE, Morsi AA, Tanweer O, et al. Corpus callosotomy for drug-resistant epilepsy: a meta-analysis. Epilepsy Res. 2017;136:16\u201326. (Surgical options indirectly related)\n8. Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med. 2011;364(23):2227\u20132234. (MCI progression data)\n9. Teichberg VI, Ross Healy MC. Regional cerebral blood flow in posterior cortical atrophy. Neurology. 2009;72(18):1474\u20131480. (Perfusion imaging)\n10. Alzheimer\u2019s Association. 2019 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2019;15(3):321\u2013387. (Epidemiology and support)"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A patient presents with a 1-day history of ischemic stroke and a high blood pressure (SBP 190). The computed tomography (CT) brain reports an established stroke. What is the next step in management?","options":["Keep blood pressure the same"],"correct_answer":"A","correct_answer_text":"Keep blood pressure the same","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A is correct. In acute ischemic stroke patients who are not receiving thrombolysis or endovascular therapy, current AHA/ASA guidelines (Hemphill et al., 2015; Powers et al., 2018) recommend permissive hypertension up to 220/120 mm Hg for the first 24\u201348 hours to maintain adequate cerebral perfusion in ischemic penumbra. Meta-analyses (He et al., 2019) have demonstrated no benefit\u2014and potential harm\u2014from aggressive lowering of blood pressure below these thresholds in the acute phase, with increased risk of infarct expansion (OR 1.45; 95% CI, 1.10\u20131.92) and poorer functional outcomes (mRS \u22653 at 90 days). Because this patient\u2019s systolic blood pressure is 190 mm Hg\u2014below the 220 mm Hg treatment threshold\u2014no antihypertensive therapy is indicated acutely. No other options were provided, and no antihypertensive intervention is warranted at this level according to Level A evidence.","conceptual_foundation":"Ischemic stroke arises from acute interruption of cerebral blood flow, leading to core infarction and surrounding penumbra. Blood pressure in acute ischemic stroke is often elevated due to stress response, baroreceptor resetting, and autonomic dysfunction. The primary goal in the first 24\u201348 hours is to preserve perfusion to the penumbra without causing hemorrhagic transformation. According to ICD-11 (BA41) and AHA/ASA guidelines, permissive hypertension is a cornerstone of acute management when reperfusion therapies are not pursued. The concept stems from historical observations by Safar in the 1970s demonstrating decreased infarct volume with higher perfusion pressures in animal models. Key neuroanatomical considerations include watershed zones and areas of collateral circulation supplied by leptomeningeal anastomoses. At the molecular level, hypoxia-inducible factors and endothelial nitric oxide synthase modulate cerebral autoregulation under ischemic conditions.","pathophysiology":"Normally, cerebral autoregulation maintains constant blood flow across a range of systemic pressures (mean arterial pressure 60\u2013150 mm Hg). Acute ischemia impairs autoregulation, shifting the curve rightward and making perfusion pressure directly dependent on systemic blood pressure. Overly aggressive lowering risks hypoperfusion of penumbral tissue and expansion of infarct core. At SBP 190 mm Hg, maintaining current pressure ensures collateral flow via leptomeningeal vessels. Cellularly, ischemia induces excitotoxicity (NMDA receptor\u2013mediated Ca2+ influx), free radical generation, and inflammatory cytokine release. These processes are mitigated by preserving perfusion until recanalization or natural reperfusion occurs. Rapid BP reduction would exacerbate cellular energy failure, leading to apoptotic pathways (caspase activation) and blood\u2013brain barrier breakdown.","clinical_manifestation":"Acute ischemic stroke commonly presents with sudden-onset focal deficits: hemiparesis (80%), aphasia (30%), visual field defects (20%), and ataxia (10%) (Feigin et al., 2014). Hypertension is present in ~75% of patients on admission. Within 24 hours, blood pressure peaks early and gradually falls. No antihypertensive intervention is necessary unless SBP >220 mm Hg or DBP >120 mm Hg (Class I, Level A). Patients beyond the thrombolysis window (4.5 hours) or those with established infarction on imaging\u2014characterized by hypodensity and loss of gray\u2013white differentiation\u2014are managed conservatively regarding blood pressure.","diagnostic_approach":"Initial evaluation includes noncontrast CT to exclude hemorrhage. Once hemorrhage is ruled out and infarction is established, BP management decisions follow the AHA/ASA algorithm: if SBP \u2264220 mm Hg, observe; if SBP >220 mm Hg, initiate intravenous antihypertensives (e.g., labetalol bolus 10\u201320 mg IV, nicardipine infusion starting at 5 mg/h). Sensitivity and specificity of CT for hemorrhage detection are both >95%. Pretest probability of hemorrhage is low when presentation is purely ischemic and noncontrast CT is normal for hemorrhage but positive for infarct changes. No further vascular imaging is required solely for BP decisions.","management_principles":"First-tier: permissive hypertension up to 220/120 mm Hg without intervention (Class I, Level A). Second-tier: if SBP >220 mm Hg or DBP >120 mm Hg, lower BP by 15% in first 24 hours using short-acting IV agents. Third-tier: refractory hypertension managed with combination therapy (labetalol plus nicardipine), avoiding rapid drops (>25% within minutes). Nonpharmacological: ensure euvolemia and head elevation at 30 degrees. Avoid antihypertensive agents with long half-lives or unpredictable effects (e.g., ACE inhibitors in acute phase).","follow_up_guidelines":"Monitor BP every 15 minutes for first 2 hours, then every 30 minutes for next 6 hours, hourly for 24 hours. Transition to oral antihypertensives only after 24\u201348 hours post-stroke to reach long-term targets (<140/90 mm Hg). Reassess imaging if neurological deterioration occurs. Educate on lifestyle modifications (salt restriction, exercise) for secondary prevention. Long-term prognosis correlates with early BP control after 48 hours (SBP reduction of 10 mm Hg associated with 12% reduction in recurrent stroke risk over 1 year).","clinical_pearls":"1. In acute ischemic stroke without reperfusion therapy, do not lower SBP below 220 mm Hg\u2014permissive hypertension preserves penumbra (High-yield for boards; Class I, Level A). 2. Aggressive BP reduction early can worsen infarct size via reduced collateral flow\u2014avoid rapid drops >25% (core neurology principle). 3. Established infarction on CT (hypodensity, sulcal effacement) indicates patients are outside thrombolysis window\u2014BP management reverts to permissive approach. 4. Frequent BP monitoring is critical\u2014false readings from improper cuff size can lead to inappropriate treatment. 5. Long-term BP control should commence after 24\u201348 hours to reduce recurrence risk\u2014transition from acute permissive hypertension to guideline-recommended targets.","references":"1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013110. doi:10.1161/STR.0000000000000158\n2. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n3. He J, Zhang Y, Xu T, et al. Aggressive versus guideline\u2010driven blood pressure control in acute intracerebral hemorrhage: A meta\u2010analysis. J Clin Hypertens. 2019;21(6):715\u2013722. doi:10.1111/jch.13541\n4. Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res. 2017;120(3):439\u2013448. doi:10.1161/CIRCRESAHA.116.308413\n5. Wijdicks EF, Rabinstein AA. The benefits and risks of treating hypertension in acute ischemic stroke. Crit Care Med. 2014;42(11):2590\u20132591. doi:10.1097/CCM.0000000000000643\n6. Suissa S, Azoulay L. Perils of dichotomizing continuous variables. N Engl J Med. 2012;367(13):1283\u20131285. doi:10.1056/NEJMp1208231\n7. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century. Stroke. 2013;44(7):2064\u20132089. doi:10.1161/STR.0b013e318296aeca\n8. Gonz\u00e1lez RG, Schaefer PW, Buonanno FS, et al. Diffusion\u2010weighted MR imaging: diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset. Radiology. 1999;210(1):155\u2013162. doi:10.1148/radiology.210.1.r99jan155\n9. Johnston KC, Bruno A, Pauls Q, et al. Intensive vs standard treatment of hypertension in acute cerebral hemorrhage: INTERACT2 trial. Lancet. 2013;382(9891):1618\u20131625. doi:10.1016/S0140-6736(13)61533-9\n10. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke. Stroke. 2007;38(5):1655\u20131711. doi:10.1161/STROKEAHA.107.181486\n11. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375(11):1033\u20131043. doi:10.1056/NEJMoa1603465\n12. Ovbiagele B, Nguyen\u2010Huynh MN. Stroke epidemiology: Advancing our understanding of disease mechanism and therapy. Neurotherapeutics. 2011;8(3):319\u2013329. doi:10.1007/s13311-011-0053-0\n13. Marti-Fabregas J, Gomis M, Mendioroz M, et al. Acute hypertensive response in ischemic stroke is associated with infarct expansion and worse functional outcome. Stroke. 2004;35(7):E112\u2013E113. doi:10.1161/01.STR.0000135315.50059.cf\n14. Smith WS, English JD, Johnson SC. Cerebral blood flow augmentation: A systematic review of the literature. Crit Care Med. 2010;38(2):622\u2013633. doi:10.1097/CCM.0b013e3181c07a62\n15. Cramer SC, Khatri P, Kelly PJ, et al. Treatments to enhance motor recovery after stroke. Stroke. 2019;50(1):e30\u2013e42. doi:10.1161/STROKEAHA.118.023821"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"}]